GET DAILY SIGNALSTrevi Therapeutics (TRVI) Reports Wider Q3 Loss but Maintains Strong Cash Runway
Key Takeaways
- Trevi Therapeutics reported a third quarter 2026 net loss of $21.5 million, compared with a net loss of $11.8 million in the same period of 2025.
- Net loss per share came in at $0.13, slightly ahead of the consensus estimate of roughly $0.14 per share.
- The company ended the quarter with $299.4 million in cash, cash equivalents and marketable securities, which management expects to fund operations into 2030.
- Research and development (R&D) expenses rose to $19.1 million from $10.1 million a year earlier, reflecting stepped-up spending on the Phase 3 OCEAN-1 and OCEAN-2 trials.
- The company initiated its Phase 3 OCEAN-2 trial during the quarter, with both OCEAN pivotal studies now recruiting patients.
Why the Quarter Matters
Trevi Therapeutics is a clinical-stage biopharmaceutical company advancing Haduvio (nalbuphine ER) as a potential first-in-class option for chronic cough, focused on idiopathic pulmonary fibrosis (IPF)-related cases and refractory chronic cough (RCC). As a pre-revenue firm, its results draw attention mainly to cash reserves and trial execution rather than revenue. I track enrollment progress in the pivotal studies and capital efficiency closely. This update followed setbacks among competitors in the RCC space, leaving TRVI among the few active players in chronic cough, so clinical and regulatory details carried particular weight alongside the headline numbers.
The Reported Figures
For the third quarter ended September 30, 2026, TRVI posted a net loss of $21.5 million, up from $11.8 million in the prior-year quarter. Loss per share was $0.13, a bit better than the consensus estimate of about $0.14. R&D spending climbed to $19.1 million from $10.1 million, driven by costs for the Phase 3 OCEAN-1 and OCEAN-2 trials, the Phase 2b LAKE study, and higher stock-based compensation. General and administrative expenses increased to $5.4 million from $3.8 million, while other income rose to $3.0 million from $2.1 million thanks to interest on a larger cash balance. The company finished the period with $299.4 million in cash, cash equivalents, and marketable securities, and it reiterated that this should support operations into 2030, covering the IPF program through potential FDA approval as well as the non-IPF interstitial lung disease and RCC efforts. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Sentiment
Investor attention centered more on balance-sheet strength and clinical momentum than on the wider loss. The extended cash runway and active recruitment in both Phase 3 OCEAN trials reinforced the view that the company is positioned through upcoming data readouts. Recent competitive setbacks in RCC have left TRVI as one of the remaining contenders in chronic cough. Positive FDA feedback on the non-IPF ILD program and a newly allowed patent further supported confidence in the regulatory path.
Forward Catalysts to Watch
Clinical milestones will drive the story more than financial metrics. Topline results from Phase 3 OCEAN-2 are expected in the second half of 2027 and from OCEAN-1 in the first half of 2028. Near term, the sample-size re-estimation analysis for the Phase 2b LAKE trial in RCC is due early in the first quarter of 2027 and will clarify whether the study needs expansion or faces futility risks. A Phase 2 dose-ranging study in non-IPF ILD-related chronic cough is planned for the first quarter of 2027, with data expected in the first half of 2028. Enrollment pace and any additional regulatory input remain important factors for the cash outlook.
Integrating AI into My Research Process
When evaluating clinical-stage names like this, I find Tickeron’s AI Trend Prediction Engine useful for quickly assessing how technical patterns and momentum align with fundamental developments. It helps surface comparable setups across the sector without requiring hours of manual chart review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TRVI sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for TRVI moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 57 cases where TRVI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for TRVI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TRVI's RSI Oscillator exited the oversold zone, 20 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on TRVI as a result. In 74 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for TRVI just turned positive on October 20, 2026. Looking at past instances where TRVI's MACD turned positive, the stock continued to rise in 40 of 50 cases over the following month. The odds of a continued upward trend are 80%.
TRVI moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRVI advanced for three days, in 240 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
TRVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.350) is normal, around the industry mean (3.498). P/E Ratio (-40.943) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 23 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. TRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of neurological products
Industry Biotechnology
Advertisement